Tauriga Sciences, Inc. to Complete the Increase of Authorized Shares Prior to Filing Fiscal Year 2015 Annual Report (Form 10K)

Ein Arzt berät einen Patienten (Symbolbild). © TommL / Vetta / Getty Images https://www.gettyimages.de/

PR Newswire

NEW YORK, July 14, 2015

NEW YORK, July 14, 2015 /PRNewswire/ -- Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or "the Company"), a diversified life sciences company, today announced that the Company has decided to complete the proposed increase in authorized shares of common stock from 1 billion to 2.5 billion as more fully described in the Preliminary Schedule 14A filed with the Securities and Exchange Commission prior to filing its Annual Report on Form 10-K for the fiscal year ended March 31, 2015 ("Form 10-K"). The Company anticipates that it will be filing and mailing the Definitive Schedule 14A with the location and time of the special shareholder meeting. The Company will proceed to file its Form 10-K shortly thereafter and, if so, will not be at any risk of being delisted from the OTCQB exchange from the delay of filing Form 10-K.

Tauriga's CEO, Seth M. Shaw stated, "Based on conversations with the Company's legal counsel and independent auditor, the Board of Directors of the Company have decided this is the most responsible course of action to ensure an accurate Form 10-K. The Company fully expects to file its Form 10-K annual report during the last week of July 2015. The Company continues to make meaningful progress in its business initiatives and looks forward to a successful second quarter of 2015."

About TAURIGA SCIENCES, INC.:

Tauriga Sciences, Inc. (OTCQB: TAUG) is a diversified life sciences company focused on generating profitable revenues through its present and future holdings. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company's corporate website at www.tauriga.com

NON SOLICITATION:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:

ARIVA.DE Börsen-Geflüster

Kurse

Tauriga Sciences

- $

0,00%

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

Contact:
Mr. Seth M. Shaw,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
New York City: + 1-917-796-9926
Montreal: +1-514-840-3697
Email: sshaw@tauriga.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tauriga-sciences-inc-to-complete-the-increase-of-authorized-shares-prior-to-filing-fiscal-year-2015-annual-report-form-10k-300113170.html

SOURCE Tauriga Sciences, Inc.

Mehr Nachrichten zur Tauriga Sciences Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.